-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lung cancer is one of the most threatening malignancies to human health and life, and the number of deaths due to lung cancer accounts for about one-fifth of all cancer deat.
Recently, the 2022 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer (IASLC) was held in Vienna, Austria in a combination of online and offline metho.
Chi-Med: Sivotinib
Chi-Med: SivotinibFrom 0 to 1 , a new weapon for precision treatment of non-small cell lung cancer was born!
From 0 to 1 , a new weapon for precision treatment of non-small cell lung cancer was born!Sivotinib is the world's first selective MET inhibitor independently developed in Chi.
Sivotinib is the world's first selective MET inhibitor independently developed by Chi.
Chi-Med is an innovative commercial-stage biopharmaceutical company dedicated to the discovery, global development and commercialization of targeted medicines and immunotherapies for the treatment of cancer and immune diseas.
Dizhe Medicine: Suvatinib
Dizhe Medicine: SuvatinibThe first national innovative drug in the field of lung cancer that has obtained the "Double Breakthrough Therapy Designation" in China and the United States is on the stage!
The first national innovative drug in the field of lung cancer that has obtained the "Double Breakthrough Therapy Designation" in China and the United States is on the stage!Suvatinib is a highly selective EGFR tyrosine kinase inhibitor (TKI) independently developed in China targeting multiple EGFR mutant subtypes, and is currently in the global key registration clinical sta.
At this WCLC conference, Dizhe announced the latest research results of suvatinib in the treatment of advanced non-small cell lung cancer with EGFR exon 20ins insertion mutation (EGFR exon20ins) who had previously failed platinum-containing chemothera.
The data showed that the best objective response rate ( ORR ) of suvatinib was 54% , and the ORR was 44% for patients with brain metastases at baseline , demonstrating good safety and efficac.
Looking forward to the future, suvatinib is expected to solve the unmet clinical needs in the field of lung canc.
CStone: Sugelimumab
A new milestone, sugelimab opens a new era of immunotherapy for non-small cell tumors in China!
A new milestone, sugelimab opens a new era of immunotherapy for non-small cell tumors in China!The results of the GEMSTONE-301 study of CStone, a Hong Kong-listed innovative pharmaceutical company, were announced in the form of an oral report of the Chairman's Forum at the 2022 World Lung Cancer Congre.
Sugalimab is a natural G-type immunoglobulin 4 (IgG4) monoclonal antibody drug developed by CStone that is closest to the human bo.
In patients with unresectable stage III non-small cell lung (NSCLC ) cancer who did not have disease progression after concurrent or sequential chemoradiotherapy, sugalimab showed sustained benefit compared with place.
The industry believes that the results of the GEMSTONE-301 research were published at the WCLC Chairman Forum and selected for the press conference, which further illustrates the international recognition of this resear.
Yifang Bio: KRAS G12C Inhibitor
Yifang Bio: KRAS G12C Inhibitor Yifang Bio: KRAS G12C InhibitorThe first KRAS G12C inhibitor independently developed and entered into clinical trials in China has made a new breakthrough!
The first KRAS G12C inhibitor independently developed and entered into clinical trials in China has made a new breakthrough!Globally, only Amgen's Sotorasib (AMG510), an innovative KRAS G12C drug, was conditionally approved by the US FDA in May 202 No KRAS G12C inhibitor has been approved for marketing in Chi.
Yifang Bio's D-1553 product is the first KRAS G12C inhibitor independently developed and entered into clinical trials in Chin.
The current research results show that D-1553 exhibits good safety and anti-tumor efficacy in previously treated patients with advanced non-small cell lung cancer with KRAS G12C mutatio.
In previously treated patients with advanced non-small cell lung cancer with KRAS G12C mutation, D-1553 demonstrated good safety and anti-tumor effica.
On July 25, Yifang Bio was officially listed on the Science and Technology Innovation Boa.
At present, Yifang Bio has 1 product in the new drug marketing application stage, 3 products in the clinical trial stage and 5 preclinical research projec.
At this stage, D-1553 became one of the company's core competenci.
Lung cancer is the second largest malignant tumor in the wor.
I hope these research results will eventually benefit the majority of lung cancer patients!
I hope these research results will eventually benefit the majority of lung cancer patients!
